Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
AstraZeneca says it will invest $190 million to build a new production plant in Macclesfield, England, to make its Zoladex injectable drug for treating prostate cancer. The plant is due to open in 2017. The investment secures the jobs of 300 staff at the existing Zoladex facilities in Macclesfield, AstraZeneca says. The firm selected Macclesfield so that it can draw on local expertise gathered from more than two decades of Zoladex production in the town. Zoladex is currently the firm’s fifth-largest-selling drug, with annual sales of about $1 billion.
This article has been sent to the following recipient: